Novartis signed five virtual power purchase agreements (VPPAs), which are expected to collectively add 277 megawatts of clean power to the electrical grid. This move makes Novartis the first pharmaceutical company set to achieve 100% renewable electricity in its European operations. The projects are expected to address Novartis greenhouse gas emissions across its European operations, equivalent to removing approximately 113 000 passenger vehicles from the road annually.
“At Novartis, environmental sustainability is aligned with our purpose to reimagine medicine to improve and extend people’s lives,” said Montse Montaner, Chief Sustainability Officer at Novartis. “Energy efficiency and renewable energy solutions are the cornerstones of our strategy for reducing emissions. These agreements mark a major milestone on the Novartis environmental sustainability journey to be carbon neutral across its operations by 2025 and across its supply chain by 2030.”
At Novartis, environmental sustainability is closely aligned with our wider purpose to reimagine medicine for people all around the world. We have embraced ambitious targets to achieve full carbon neutrality (Scope 1, 2 and 3), as well as water and plastic neutrality by 2030.